Technology
Health
Pharmaceutical
Amneal Pharmaceuticals
$8.099876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$8.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (0.48%) Today
-$0.20 (-2.41%) After Hours
Why Robinhood?
You can buy or sell AMRX and other stocks, options, ETFs, and crypto commission-free!
About
Amneal Pharmaceuticals, Inc. Class A Common Stock, also called Amneal Pharmaceuticals, is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. Read More It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
Employees
6,000
Headquarters
Bridgewater, New Jersey
Founded
2002
Market Cap
1.06B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.10M
High Today
$8.33
Low Today
$7.90
Open Price
$8.25
Volume
415.10K
52 Week High
$24.48
52 Week Low
$7.90
Collections
Technology
Health
Pharmaceutical
2018 IPO
US
North America
News
Barron'sMay 24
The Qualcomm Sell-Down Is Overdone
Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s. Some of the reports’ issuers have provided, or hope to provide, investment-banking or other services to the companies being analyzed. Qualcomm QCOM-Nasdaq Buy Price $76.62 on May 20 by Canaccord Genuity Following the U.S. Commerce Department’s addition of Huawei and its ...
Seeking AlphaMay 9
Amneal Pharmaceuticals' CEO Rob Stewart on Q1 2019 Results - Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Mark Donohue – Vice President of Investor Relations and Corporate Communications Rob Stewart – President and Chief Executive Officer Todd Branning – Chief Financial Officer Joe Todisco – Senior Vice President of Specialty Commercial Conference Call Participants Jennifer Kim – Cantor Fitzgerald Gary Nachman – BMO Capital Markets David Amsellem – Piper Jaffray Eason Lee – SVB Leerink...
NasdaqMay 9
Why Amneal Pharmaceuticals Stock Is Cratering Today
What happened Shares of the generic and specialty drug makerAmneal Pharmaceuticals (NYSE: AMRX) fell by more than 19% in early-morning trading today on heavy volume. The culprit? Amneal released its first-quarter earnings report before the opening bell this morning, and it apparently didn't go over well with investors. Although the company beat consensus on revenue by a modest $7.4 million (approximately 1.7% higher than expected), Amneal also posted a hefty net loss of $125 million for the quarter. Imag...
Price Paid on Robinhood
38% Lower
Right Now
52 Week Low
$7.90
Average Price Paid
$13.05
52 Week High
$24.48
Earnings
$0.14
$0.20
$0.27
$0.33
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Available Aug 8, Pre-Market